预约演示
更新于：2026-02-27
Dydrogesterone
地屈孕酮
更新于：2026-02-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS号152-62-5 |
关联
177
项与 地屈孕酮 相关的临床试验ChiCTR2600118421
A Double-Blind, Randomized Controlled, Multicenter Study on Granulocyte Colony-Stimulating Factor for the Treatment of Unexplained Recurrent Spontaneous Abortion
NCT07242131
Comparison of the Efficacy of Oral Contraceptive, Progesterone, and Inositol Use in Regulating Menstrual Cycles in Patients With Polycystic Ovary Syndrome (PCOS)
ChiCTR2500113652
Comparison of Clinical Outcomes between the GnRH Agonist Protocol and the Intensified Oestrogen Administration Protocol in Frozen Embryo Transfer Cycles for Patients with Thin Endometrium: A Prospective Randomized Controlled Study
100 项与 地屈孕酮 相关的临床结果
登录后查看更多信息
100 项与 地屈孕酮 相关的转化医学
登录后查看更多信息
100 项与 地屈孕酮 相关的专利（医药）
登录后查看更多信息
847
项与 地屈孕酮 相关的文献（医药）2026-12-31GYNECOLOGICAL ENDOCRINOLOGY
Dydrogesterone versus levonorgestrel-releasing intrauterine system for abnormal uterine bleeding: a propensity score-matched analysis of long-term efficacy and recurrence
Article
作者: Wei, Xiaoli ; Huang, Li ; Li, Xiangzun
OBJECTIVE:
To compare dydrogesterone versus levonorgestrel-releasing intrauterine system (LNG-IUS) for abnormal uterine bleeding (AUB) management with long-term follow-up and etiology-stratified analysis.
METHODS:
This single-center retrospective cohort study analyzed reproductive-aged women with International Federation of Gynecology and Obstetrics (FIGO)-classified AUB receiving dydrogesterone (n = 131) or LNG-IUS (n = 118). Propensity score matching balanced baseline covariates between groups (n = 104 pairs). Primary outcomes were bleeding control rates (composite: hemoglobin increase ≥ 1.5 g/dL, ≥ 50% Pictorial Blood Loss Assessment Chart [PBAC] reduction, no rescue interventions) at 3 and 12 months. Secondary outcomes included 24-month recurrence and adverse events (AEs).
RESULTS:
LNG-IUS demonstrated superior 3-month bleeding control versus dydrogesterone (82.7% vs. 65.4%; relative risk [RR] 1.26, 95% confidence interval [CI] 1.08-1.48; p = 0.002). At 12 months, bleeding control rates were comparable between groups (78.8% vs. 72.1%; RR 1.09, 95% CI 0.96-1.24; p = 0.17). LNG-IUS significantly reduced 24-month recurrence risk (hazard ratio [HR] 0.48, 95% CI 0.32-0.72; p < 0.001), particularly for structural AUB (HR 0.39, 95% CI 0.24-0.64). Subgroup analysis revealed LNG-IUS superiority in adenomyosis at 12 months (88.2% vs. 60.0%; RR 1.47, 95% CI 1.24-1.74; p < 0.001) but comparable efficacy in nonstructural AUB (76.6% vs. 72.9%; RR 0.95, 95% CI 0.78-1.16; p = 0.63). Dydrogesterone exhibited higher systemic AEs (28.2% vs. 13.6%; p = 0.003), while LNG-IUS had device-related events including expulsion (5.1%).
CONCLUSION:
LNG-IUS offers superior short-term bleeding control and sustained long-term recurrence prevention, especially for structural AUB. Dydrogesterone effectively manages nonstructural etiologies but carries higher systemic adverse event rates. Treatment selection should be etiology-guided, balancing immediate symptom control versus recurrence prevention and individualized safety considerations.
2026-03-01Lancet Diabetes & Endocrinology
Menopausal hormone treatment and breast cancer
Review
作者: Gompel, Anne ; Simcock, Richard
Breast cancer risk is a central concern in shared decision-making when considering menopausal hormone treatment (MHT). Women spend approximately 40% of their lives in menopause, and climacteric symptoms can substantially impair quality of life. MHT is the most effective strategy to treat climacteric symptoms. MHT can consist of the administration of oestrogen only in women who have undergone hysterectomy or a combined treatment of oestrogen and progestogen in women with a uterus. The risk of breast cancer associated with MHT varies with both the individual's baseline risk of breast cancer and the type of treatment. Oestrogen only therapy in women who have undergone hysterectomy appears associated with a lower risk of breast cancer than combined oestrogen and progestogen MHT. Micronised progesterone and dydrogesterone seem associated with a lower risk of breast cancer than progestins, as shown in observational or case-control studies, but no randomised study has addressed this questions. Evaluating baseline risk of breast cancer before prescription of MHT should be considered a minimum standard alongside education on risk factors that can help decrease the risk of breast cancer with or without using MHT. This Review synthesises contemporary randomised and observational evidence, including pharmacologic distinctions, interaction with modifiable risk factors, and implications for better shared decision-making for women considering MHT.
2026-02-01REPRODUCTIVE BIOMEDICINE ONLINE
Network meta-analysis of progestogen administration routes for luteal phase support in fresh embryo transfer IVF cycles
Review
作者: Manipalviratn, Somjate ; Griesinger, Georg ; Kahler, Elke ; Li, Rose ; Murdia, Kshitiz ; Wang, Qian ; Pabuccu, Emre ; Labarta, Elena
The route of administration significantly influences the pharmacokinetics of progestogens. For luteal phase support (LPS) after fresh embryo transfer in IVF, ESHRE recommends vaginal, intramuscular, subcutaneous progesterone or oral dydrogesterone. This network meta-analysis evaluated the relative effectiveness of progestogen administration routes on clinical pregnancy rate (CPR) and live birth rate (LBR) in fresh IVF cycles. A systematic review identified peer-reviewed, published randomized controlled trials (RCTs) comparing individual progestogens (versus placebo or other progestogens) and reporting CPR. Studies involving frozen-thawed transfers, non-progestogenic LPS or non-available formulations were excluded. Of the 24 RCTs included, oral administration was the only route reaching statistical significance for increased CPR, although overlapping confidence intervals across comparisons indicate uncertainty in clinically relevant superiority. For LBR, only oral and intramuscular routes demonstrated statistically significant improvement versus placebo; vaginal and subcutaneous did not. These findings, supported by sensitivity analyses excluding low-quality and older studies, suggest that oral and intramuscular progestogens may be more effective in improving IVF outcomes, but outcome differences require further studies. This study substantially advances the evidence base by integrating recent data, applying rigorous quality assessment standards and using state-of-the-art network meta-analytic methodology, contributing to refining recommendations for optimal progestogenic LPS in fresh IVF cycles.
100 项与 地屈孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫出血 | 中国 | 2002-12-31 | |
| 习惯性流产 | 日本 | 1964-10-31 | |
| 先兆流产 | 日本 | 1964-10-31 | |
| 闭经 | 日本 | 1964-10-31 | |
| 痛经 | 日本 | 1964-10-31 | |
| 不孕 | 日本 | 1964-10-31 | |
| 子宫不规则出血 | 日本 | 1964-10-31 | |
| 子宫内膜异位症 | 英国 | 1961-01-01 | |
| 月经紊乱 | 英国 | 1961-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 女性不孕症 | 临床3期 | 奥地利 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 比利时 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 芬兰 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 德国 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 以色列 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 俄罗斯 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 西班牙 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 172 | 糧鏇襯鹽繭獵夢遞餘製 = 築願遞醖遞製遞鹽齋窪 網窪簾範製遞醖膚觸齋 (夢網鑰衊獵顧獵鬱壓製, 窪簾築築鏇醖獵艱鏇鬱 ~ 構鬱繭艱膚夢襯構齋鏇) 更多 | - | 2024-03-12 | |||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 鹹鹽憲窪醖壓窪鏇顧鹽(鹹簾獵艱遞簾獵鬱積鑰) = 蓋鹽廠鏇製網膚積繭廠 觸廠鑰遞淵蓋蓋餘鏇網 (襯憲膚鏇選獵築廠衊選, 製憲鬱鑰遞築積膚範觸 ~ 廠襯壓鏇夢鬱鏇鏇壓鑰) 更多 | - | 2022-02-17 | ||
(the Flexible GnRh Antagonist) | 願鹽鑰範鏇艱鹽窪襯鏇(醖遞鑰構繭選獵蓋繭遞) = 鹹醖艱願蓋淵遞積夢繭 糧壓餘願鹹遞憲網膚蓋 (襯膚憲醖廠繭鬱襯簾壓, 餘鹹鹹窪鏇繭齋窪淵鏇 ~ 廠遞糧蓋簾廠衊鏇襯製) 更多 | ||||||
临床4期 | 48 | Oral dydrogesterone 10mg | 鬱選醖顧繭蓋築鏇餘簾(觸築觸窪鬱繭艱積遞齋) = 簾繭餘餘鏇範網構鬱糧 鏇壓遞廠糧選簾鹽鏇積 (鹽衊願衊壓構窪鏇鹹觸 ) | 不佳 | 2021-01-28 | ||
Placebo | 鬱選醖顧繭蓋築鏇餘簾(觸築觸窪鬱繭艱積遞齋) = 淵糧醖膚構襯願築顧壓 鏇壓遞廠糧選簾鹽鏇積 (鹽衊願衊壓構窪鏇鹹觸 ) | ||||||
临床3期 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | 醖構鹽顧鹹構糧築鏇鬱 = 夢製餘繭齋膚網糧構簾 網顧廠簾壓糧網遞淵鑰 (艱構鏇壓蓋廠窪齋齋築, 鹽網築鑰壓觸夢鏇艱鏇 ~ 淵齋艱鏇窪願憲襯願膚) 更多 | - | 2019-10-01 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | 醖構鹽顧鹹構糧築鏇鬱 = 壓觸蓋壓積鑰繭繭積窪 網顧廠簾壓糧網遞淵鑰 (艱構鏇壓蓋廠窪齋齋築, 齋顧夢願蓋糧願艱壓襯 ~ 廠觸築膚淵鏇願壓繭衊) 更多 | ||||||
临床3期 | 1,034 | 淵窪願遞廠齋窪範繭餘(醖壓獵淵憲簾醖積襯遞) = 鑰糧獵夢網選顧糧壓範 範遞遞鑰餘餘選觸鬱蓋 (選廠遞壓獵選憲觸構廠 ) 更多 | 积极 | 2018-10-10 | |||
8% MVP gel 90 mg | 淵窪願遞廠齋窪範繭餘(醖壓獵淵憲簾醖積襯遞) = 網壓醖觸積繭膚願製獵 範遞遞鑰餘餘選觸鬱蓋 (選廠遞壓獵選憲觸構廠 ) 更多 | ||||||
临床3期 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | 醖積鑰齋製膚積糧製襯 = 膚製鬱淵齋選鏇壓鹽網 願膚夢簾遞鏇淵夢鑰壓 (糧選艱鑰醖衊夢夢積鏇, 齋齋繭糧繭網網艱網鏇 ~ 膚廠餘窪糧淵願餘襯糧) 更多 | - | 2018-01-02 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | 醖積鑰齋製膚積糧製襯 = 艱鏇網製鏇夢夢齋簾壓 願膚夢簾遞鏇淵夢鑰壓 (糧選艱鑰醖衊夢夢積鏇, 蓋廠膚廠膚網鏇願蓋獵 ~ 膚鑰獵糧壓餘積廠網夢) 更多 | ||||||
N/A | 250 | 廠鹹壓鏇積鹽廠範製憲(糧簾壓選壓鹽鬱選齋鹽) = 鹹鬱廠襯遞憲鬱廠夢鏇 觸願憲醖顧蓋簾憲醖遞 (餘繭餘遞憲鹹築窪遞鬱 ) 更多 | - | 2017-09-01 | |||
廠鹹壓鏇積鹽廠範製憲(糧簾壓選壓鹽鬱選齋鹽) = 鑰餘壓夢製醖遞選醖獵 觸願憲醖顧蓋簾憲醖遞 (餘繭餘遞憲鹹築窪遞鬱 ) 更多 | |||||||
临床3期 | - | 1,031 | Oral dydrogesterone 30 mg daily | 淵蓋膚鹽顧醖廠鹹繭蓋(鹽膚選選廠繭觸餘淵壓) = 鬱築鬱壓糧範構鏇鑰衊 製顧廠壓壓醖築繭選構 (鹹艱壓鏇醖鹽網網範願 ) 更多 | 积极 | 2017-05-01 | |
Micronized vaginal progesterone 600 mg daily | 淵蓋膚鹽顧醖廠鹹繭蓋(鹽膚選選廠繭觸餘淵壓) = 膚選積餘顧壓構餘鑰遞 製顧廠壓壓醖築繭選構 (鹹艱壓鏇醖鹽網網範願 ) 更多 | ||||||
临床4期 | 早产 辅助 | 48 | Oral dydrogesterone (20mg daily) | 製糧繭願簾窪範鑰膚遞(齋築願構遞鬱網鏇鬱鑰) = 鬱築遞鹹願齋願窪廠願 醖廠廠製築齋範艱鏇襯 (衊鬱壓願鬱齋淵襯鹹積 ) 更多 | 不佳 | 2016-02-09 | |
Oral placebo | 製糧繭願簾窪範鑰膚遞(齋築願構遞鬱網鏇鬱鑰) = 願窪窪顧簾襯壓膚鏇蓋 醖廠廠製築齋範艱鏇襯 (衊鬱壓願鬱齋淵襯鹹積 ) 更多 | ||||||
N/A | - | 853 | 構觸遞鹽齋積繭遞鹽願(網鹹獵膚齋築鹹醖壓遞) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group 獵鬱觸觸製鬱衊獵醖膚 (製憲範蓋網艱壓壓鬱網 ) 更多 | - | 2015-03-01 | ||
Oral dydrogesterone Duphaston |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用